Polymorphisms of β1-Adrenoreceptor Gene and Cardiovascular Complications in Patients with Thyrotoxicosis

Table 3

(a) Clinical and laboratory data of patients with thyrotoxicosis depending on genotype (Gly389Arg) before treatment. (b) Clinical and laboratory data of patients with thyrotoxicosis depending on genotype (Gly389Arg) after treatment.

(a)

Variables	CC, 𝑛=62	CG, 𝑛=94	GG, 𝑛=9
Sex, male/female	F: 56 (39.4%); M: 6 (26%)	F: 78 (55%); M: 16 (69.6%)	F: 8 (5.6%); M: 1 (4.4%)
Age, years	43.3 ± 9.5	42.1 ± 8.9	40.5 ± 9.8
Duration of thyrotoxicosis, month	58; 10; (6; 24)	90; 10; (7; 20)	8; 7; (5.5; 10)
HR, beats/min	92 ± 12	99 ± 23	90 ± 6
BP, systolic, mmHg	129 ± 16	129 ± 15	134 ± 20
BP, diastolic, mmHg	76 ± 10	76 ± 9	77 ± 12
FT3, pmol/L	20; 12.7; (7.2; 22.3)	37; 11.5; (9.5; 20.7)	5; 10.4; (9.7; 22.1)
FT4, pmol/L	27; 37.2; (30.4; 54.5)	45; 46.0; (28.0; 57.8)	7; 31.0; (29.4; 92.4)
T3, total, nmol/L	34; 4.8; (3.9; 6.8)	51; 5.2; (3.7; 7.8)	5; 5.8; (3.0; 5.9)
T4, total, nmol/L	36; 198; (165; 239)	49; 222; (187; 288)	3; 174; (133; 214)

(b)

Variables	CC, 𝑛=62	CG, 𝑛=94	GG, 𝑛=9
HR, beats/min	75 ± 13	79 ± 12	75 ± 4
BP, systolic, mmHg	121 ± 14	118 ± 13	122 ± 14
BP, diastolic, mmHg	73 ± 7	70 ± 9	69 ± 10
FT3, pmol/L	10; 4.1; (2.3; 7.5)	13; 6.2; (5.7; 7.9)	3; 3.7; (2.0; 5.4)
FT4, pmol/L	24; 14.0; (9.3; 20.1)	45; 14.4; (10.1; 19.6)	3; 19.4; (16.7; 27.1)
T3, total, nmol/L	9; 2.5; (1.8; 3.9)	25; 2.0; (1.6; 2.7)	2; 2.0; (1.5; 2.4)
T4, total, nmol/L	43; 116; (110; 136)	49; 99; (79; 127)	6; 81; (28; 135)